ENA Investment Capital Congratulates Gustavo Paz on His Election as CEO of Ontex
ENA Investment Capital (“ENA”), a long-term, value-oriented investment firm and the second-largest shareholder in Ontex Group NV (“Ontex” or the “Company”) owning c.15% of the Company’s outstanding shares, today issued the following statement.
ENA Investment Capital would like to congratulate Gustavo Paz on his election as CEO of Ontex. We would also like to thank sincerely the Ontex Board, GBL and the other Ontex shareholders for their vote of confidence in Gustavo.
Gustavo is a fantastic, hands-on operator and a true strategic thinker. His knowledge of the business (particularly Ontex’s turnaround potential), his track record, and his understanding of the competitive landscape is unparalleled and combine to make him an exceptional candidate to guide the company. We have the utmost confidence in his abilities as a manager and a leader. Finally, the US business and its profitability (which is a key pillar of the Ontex turnaround story) will benefit substantially from his insight in that geography.
Gustavo has been a key operating partner of ours for a number of years now and we are extremely happy for him on the achievement of this important milestone.
We would also like to highlight the fact that as a result of this promotion, we have officially ended our formal engagement with Gustavo. We consider it best that he devotes 100% of his time to his new role and more importantly there is never any question about his independence, impartiality and treatment of all shareholders and stakeholders equally. Though we will miss him, we look forward to benefiting from his hard work as Ontex’s second largest equity shareholder.
Concluding: with Gustavo as CEO, we are confident that Ontex is in the strongest possible position to turnaround and grow its business and thus to explore any discussions with disclosed (as well as any other) interested 3rd parties about potential corporate actions. He is the right person–with the relevant track record and bandwidth—to evaluate such transactions, as well as to lead any corporate action that might evolve from such discussions.
We believe that with him at the helm, Ontex has a very bright future indeed. And for our part, we remain 100% committed to our investment, and we believe there are significant value creation and savings opportunities ahead, with several paths to recovery of the share price to at least the mid-cycle value potential over the next 14 months.
We wish him and the executive team well as they embark upon this challenge.
Very Kind Regards,
ENA Investment Capital
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
ENA Investment Capital
+44 20 3772 0170
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
REPLY: Arlanis Reply Named Salesforce Implementation Partner of the Year and Community Impact Partner of the Year8.12.2022 09:30:00 CET | Press release
Arlanis Reply, the Reply Group company specialized in Salesforce solutions and services, has been recognized with two awards from Salesforce for its outstanding performance as a partner in the categories "Salesforce Implementation Partner of the Year" and "Community Impact Partner of the Year" in Germany, Austria and Switzerland. With these Partner Awards, Salesforce annually honours partner companies that have demonstrated exceptional commitment to consistently delivering high-quality implementations and business outcomes for their clients. The award for the "Salesforce Implementation Partner" was given in recognition of the variety, complexity and number of customer projects with the highest customer satisfaction. As a long-standing Salesforce Consulting Partner, Arlanis Reply convinced the jury with profound expertise and comprehensive knowledge of the entire Salesforce portfolio – as well as high quality in numerous, cross-industry customer projects. The second "Community Impact Pa
ADVA’s new OSA 3350 SePRC ™ optical cesium clock breaks records with industry’s longest holdover8.12.2022 09:00:00 CET | Press release
ADVA (FSE: ADV) today launched its latest optical cesium atomic clock solution, providing unprecedented protection for critical network infrastructure systems that rely on synchronization from GNSS. The new OSA 3350 Super ePRC (SePRC™) delivers extensive timing holdover with high-performance stability and lifetime that significantly outperforms any other solution on the market. It offers a vital lifeline to time-as-a-service (TaaS) and GNSS-backup-as-a-service (GBaaS) providers, defense organizations, communication network operators, power utilities and transportation network operators looking to mitigate the risk of jamming and spoofing attacks. As a GBaaS solution, the OSA 3350 SePRC™ provides a backup to satellite-based synchronization, helping prevent severe harm to businesses and society that long GNSS outages can cause. The new device will enable the most robust PNT solution on the market. “Across all nations, our well-being and safety are more dependent than ever on critical net
Record-Breaking Demand for Alternative Residence and Citizenship8.12.2022 08:39:00 CET | Press release
The number of high-net-worth individuals enquiring about investment migration options has more than doubled since the coronavirus was first reported three years ago, with record numbers of wealthy international investors now looking to diversify their residence and citizenship options amid unprecedented global volatility. Henley & Partners has also seen a huge surge in interest and applications from citizens of highly developed countries such as Canada, the UK, and the US compared to pre-pandemic times, with Americans now the top client nationality seeking alternative residence and/or additional citizenship. Henley & Partners CEO Dr. Juerg Steffen says with many economies now in a post-pandemic phase plagued by security, political, and economic risks, wealthy families are revisiting their priorities to ensure that their legacies, wealth, and lifestyles are protected and future-proofed. “For high-net-worth investors, the optionality of living in or conducting business in a country of th
Primary endpoint met in the CLEAR Outcomes Trial of bempedoic acid showing statistically significant relative risk reduction in major adverse CV events8.12.2022 08:00:00 CET | Press release
Daiichi Sankyo Europe, (hereafter, Daiichi Sankyo) announced today that the primary endpoint was met in the Phase 3 cardiovascular CLEAR (Cholesterol Lowering via Bempedoic acid, an ATP citrate lyase (ACL)-Inhibiting Regimen) Outcomes Trial, demonstrating statistically significant relative risk reduction in major adverse CV events (MACE-4) in patients treated with 180 mg/day bempedoic acid compared to placebo (with no or very low statin background).1,3 Comprehensive data from the CLEAR Outcomes Trial, led by US-based biotech company Esperion Therapeutics Inc., will be presented at a key medical congress in early 2023 and subsequently submitted to applicable regulatory authorities. The initial findings from the data indicate that bempedoic acid is the first oral, ACL inhibitor known to reduce both LDL-C levels and risk of major adverse CV events.1 The findings are congruent with previous significant evidence and the latest clinical guidelines highlighting that the lower a person’s LDL-C
ONWARD Reports Interim Clinical Outcomes for Implantable ARC Therapy Demonstrating Potential to Improve Blood Pressure Regulation after Spinal Cord Injury8.12.2022 07:30:00 CET | Press release
ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury (SCI), today reported interim clinical outcomes from the first ten1 people treated to regulate blood pressure with implantable ARC Therapy, ONWARD’s targeted spinal cord stimulation technique. ARC Therapy immediately improved blood pressure levels for all participants; this benefit has been sustained for the duration of the current follow-up period. Participants have also reported improved quality of life, increased energy and vitality, and reduced dizziness. Aaron Phillips, PhD, Associate Professor, Physiology and Pharmacology, Biomedical Engineering, Cardiac Sciences, Clinical Neurosciences, Cumming School of Medicine, University of Calgary, and the Principal Investigator of the HEMO study, said: “Low blood pressure has long been a hidden complication of spinal cord injury that often goes unrecognized and le